Skip to main content
. 2022 Sep 16;11(11):1511–1526. doi: 10.1002/psp4.12859

FIGURE 2.

FIGURE 2

(a) Distribution of continuous or categorical covariates from the simulated dataset (N = 5000). For eight continuous baseline covariates and four PK parameters, the probability density plot was compared; for 10 categorical covariates, the proportion of each category was compared. Red: EMILIA study (ClinicalTrials.gov identifier NCT00829166); blue: simulated. (b) Correlation matrix of the seven baseline covariates and post hoc PK parameters (CL, Q, V1, V2) with PCMIN. The number in each box is the Pearson correlation coefficient (left: EMILIA original data; right: simulated data). LOGALKPH, LOGECD, LOGALBUM, LOGAST, LOGTMBD, LOGCL, and LOGQ: natural log transformation of ALKPH, ECD, ALBUM, AST, TMBD, CL, and Q. ALBUM, albumin; ALKPH, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CL, drug clearance; ECD, extracellular domain of human epidermal growth factor receptor 2; ECOG, Eastern Cooperative Oncology Group performance status; IRFSCNT, number of disease sites; OTH, other regions; PCMIN, drug trough concentration; PHSTSET, prior trastuzumab treatment (yes/no); PK, pharmacokinetic; PRIANTHR, prior anthracycline treatment (yes/no); Q, intercompartmental clearance; TMBD, tumor burden; V1, central volume of distribution; V2, peripheral volume of distribution; VSCR, visceral disease; WEU, Western European region, WT, body weight.